Paper Details

  1. Home
  2. Paper Details

Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.

Author: CorsettiM, TackJ

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Naloxegol is a new medication that is specifically approved for the treatment of opioid-induced constipation (OIC) in non-cancer patients. It is a peripherally acting µ opioid receptor antagonist that blocks the effects of opioids in the gastrointestinal tract, while preserving the central analgesic effects of opioids. In clinical trials, naloxegol was effective in reducing constipation, and the most consistent efficacy was seen with the 25 mg dose once daily.
Paper Details　
Original Abstract of the Article :
Treatment of opioid-induced constipation (OIC) is becoming a relevant clinical challenge as most of the treatments demonstrated to be more effective than placebo in treating OIC have safety issues limiting a broad clinical application. Naloxegol is the first orally administered, peripherally acting,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1358/dot.2015.51.8.2364896

データ提供：米国国立医学図書館（NLM）

Naloxegol: A New Oasis in the Desert of Opioid-Induced Constipation

Opioid-induced constipation (OIC) is a common side effect of opioid medications. This research focuses on naloxegol, a new drug specifically designed to treat OIC. The researchers reviewed the results of clinical trials investigating the efficacy and safety of naloxegol for treating OIC in noncancer patients. This research provides valuable information about this novel treatment option for a challenging condition.

A Targeted Approach to Opioid-Induced Constipation

The researchers found that naloxegol, a peripherally acting µ opioid receptor antagonist, was effective in reducing OIC symptoms without affecting the central analgesic effects of opioids. The 25-mg dose once daily showed the most consistent efficacy in clinical trials. Furthermore, naloxegol was generally well-tolerated, with most side effects being gastrointestinal in nature and typically mild and transient. This research suggests that naloxegol could be a safe and effective treatment option for patients struggling with OIC.

Navigating the Desert of Opioid Use

This research offers a new solution for managing OIC, a common side effect of opioid medications. It's like discovering a hidden oasis of knowledge in the desert of opioid use! Naloxegol, a peripherally acting µ opioid receptor antagonist, has shown promising results in clinical trials, demonstrating its potential to improve patient outcomes. However, it is crucial to consult with a healthcare professional to determine if naloxegol is the right treatment option for you and to manage any potential side effects.

Dr.Camel's Conclusion

This study provides valuable insights into the efficacy and safety of naloxegol for treating opioid-induced constipation. It's like finding a hidden oasis of knowledge in the desert of opioid use! The findings suggest that naloxegol could be a safe and effective treatment option for patients struggling with this common side effect.

Date :
  1. Date Completed 2015-11-09
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26380386

DOI: Digital Object Identifier

10.1358/dot.2015.51.8.2364896

Related Literature

Article Analysis
・Side Effects of naloxegol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.